Study of Drug Use Pattern of Anti Tb Drugs in a Tertiary Care Teaching Hospital of Karnataka, India - Aretrospective Study
Main Article Content
Abstract
Tuberculosis is one of the leading causes of mortality and morbidity around the world, infecting approximately 8 billion people, with an annual death rate of close to 1 million. The retrospective study was undertaken to assess the prescribing pattern of anti-TB drugs. The study was carried out in the general medicine of Navodaya Medical College Hospital and Research Centre at Raichur, over a period of 3 months from September to November 2023. A total of 100 patients were incorporated in the study. Among the total population, 75% were male and 25% were females. The maximum numbers of patients were in the age group of 40 to 60 yrs. The patients were classified into normal TB and EPTB. The study shows that when compared to EPTB, PTB shows most occurrences as per the study conclusions. The often risk factor involved in TB was alcohol (50%) and smoking (50%) followed by tobacco chewing (20%). In this study majority of the patients have received first line antitubercular treatment which consist of isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin. Out these medications isoniazid, rifampicin, pyrazinamide and ethambutol are the most prescribed medications which contributes 45% of overall drugs prescribed for tuberculosis treatment. In Summary, efforts to enhance the management of tuberculosis in our tertiary care teaching hospital should focus on ensuring guideline adherence and optimizing patient care to achieve the best outcomes for individuals. The patients showed good recovery which concludes that standard prescription pattern provides a good success rate in the treatment of tuberculosis
References
http://www.who.int/tb/publications/global_report/gtbr14_main_text.pdf
Accession on 30-11-2014
Veen J, Raviglione M, Rieder HL.
Standardized tuberculosis treatment outcome monitoring in Europe.
European Respiratory Journal. 1998;12(2):505–510.
National Strategic Plan for Tuberculosis: 2017–2025 elimination by 2025.
Available from: https://tbcindia.gov.in
Hartwig SC, Siegel J, Schneider PJ.
Preventability and severity assessment in reporting adverse drug reactions.
Am J Hosp Pharm. 1992;49:2229–2232.
Patra S, Lukhmana S, Tayler Smith K, Kannan AT, Satyanarayana S, Enarson DA, et al.
Profile and treatment outcomes of elderly patients with tuberculosis in Delhi, India: Implications for their management.
Trans R Soc Trop Med Hyg. 2013;107:763–768.
Chamla D.
The assessment of patients’ health-related quality of life during tuberculosis treatment in Wuhan, China.
Int J Tuberc Lung Dis. 2004;8(9):1100–1106.
Bates I, Fenton C, Gruber J.
Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants at individual and household level.
The Lancet Infectious Diseases. 2004;4(5):267–277.
Mamani M, Majzoobi MM, Ghahfarokhi SM, Esna-Ashari F, Keramat F.
Assessment of health-related quality of life among patients with tuberculosis in Hamadan, Western Iran.
Oman Medical Journal. 2014;29(2):102–105.
World Health Organization.
Medicine Strategy 2008–2013. Geneva: WHO; 2008.
Jain S, Upadhyaya P, Goyal J, Kumar A, Jain P, Seth V, et al.
A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines.
Perspect Clin Res. 2015;6:86–90.
World Health Organization.
How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators – EDM Research Series No. 007.
WHO/DAP/93.1. Geneva: WHO; 1993
Mathew TF.
Effectiveness of knowledge-based approach for improvement of patient adherence and reducing severity of adverse drug reactions in anti-tubercular therapy.
IJPPR. 2012;3:65–70.
Habib UK et al.
Anti-tuberculous therapy-induced liver injury: Frequency, management and outcome.
JMSC. 2009;7:99–102.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.